Kenvue Inc. $KVUE Position Increased by Willis Investment Counsel

Willis Investment Counsel increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 9.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 968,276 shares of the company’s stock after buying an additional 80,129 shares during the quarter. Willis Investment Counsel owned about 0.05% of Kenvue worth $20,266,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in KVUE. Handelsbanken Fonder AB lifted its stake in Kenvue by 32.0% in the second quarter. Handelsbanken Fonder AB now owns 934,183 shares of the company’s stock valued at $19,552,000 after buying an additional 226,392 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Kenvue by 14,361.4% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 245,699 shares of the company’s stock worth $5,249,000 after acquiring an additional 244,000 shares during the period. Prudential PLC grew its position in Kenvue by 2.2% in the 2nd quarter. Prudential PLC now owns 711,080 shares of the company’s stock worth $14,883,000 after purchasing an additional 15,264 shares during the last quarter. SHEPHERD WEALTH MANAGEMENT Ltd LIABILITY Co bought a new position in Kenvue in the 2nd quarter worth about $229,000. Finally, Quilter Plc increased its stake in shares of Kenvue by 2.5% in the second quarter. Quilter Plc now owns 56,907 shares of the company’s stock valued at $1,191,000 after purchasing an additional 1,409 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE:KVUE opened at $16.19 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average of $16.22 and a 200-day moving average of $19.87. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $25.17. The firm has a market cap of $31.01 billion, a price-to-earnings ratio of 21.59, a price-to-earnings-growth ratio of 2.23 and a beta of 0.71.

Kenvue (NYSE:KVUE) last issued its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be given a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.1%. Kenvue’s payout ratio is 110.67%.

Analyst Ratings Changes

Several brokerages have recently issued reports on KVUE. JPMorgan Chase & Co. reduced their price objective on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research report on Tuesday, October 14th. Edward Jones cut Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Citigroup cut their price objective on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. Finally, UBS Group reduced their price target on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.